TG Therapeutics, Inc. TGTX
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. 10-K, Item 1
- Headquarters
- New York, NY
- Next results
- around Feb 25, 2027
Where each dollar of revenue went, FY2025
Revenue of $616.3M through the costs to a net profit of $447.2M · income statement of the 10-K
TGTX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
20 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 27, 2026 against Mar 3, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
3facts worth reading about the other 8 checks found nothing to note
-
Receivables growing faster than revenueReceivables +136.6% ($129.2M to $305.6M) vs revenue +87.3% ($329.0M to $616.3M), +49.3 pts apart
-
Cash from operations lower than net incomeCash from operations −$24.8M vs net income $447.2M (FY ending Dec 31, 2025)
-
Critical audit matters changedNew this year: Realizability of deferred tax assets (“As discussed in Note 9 to the consolidated financial statements, the Company recognizes a valuation allowance for deferred tax assets if, based on review of all available positive and negative evidence, including current and historical results of operations, future income projections, and the overal”). Same as last year: Estimate of certain product revenue reserves
-
Inventory +13.7% ($110.5M to $125.6M) vs revenue +87.3% ($329.0M to $616.3M), -73.6 pts apart
7 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
20 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
In addition, recent legislative and regulatory proposals in the United States have included “most favored nation” (“MFN”) or international reference pricing models that would tie reimbursement or net prices for certain drugs to the lowest price available in other countries. Adoption or expansion of MFN or similar reference pricing…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
We may submit additional information to the FDA which the FDA determines constitutes a major amendment to the application and thereby extends the goal date for determination of approvability of the application;
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
We may be unable to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of our approved intravenous product, which could limit our ability to expand our market opportunity and patient reach. We are conducting a Phase 3 trial evaluating a subcutaneous (SubQ) formulation of ublituximab, which…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act (ACA) made significant changes to the U.S. healthcare system, which included…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.8M | $233.7M | $329.0M | $616.3M |
| Net income | −$223.8M | $12.7M | $23.4M | $447.2M |
| Operating cash flow | −$176.2M | −$31.4M | −$40.5M | −$24.8M |
| Free cash flow | −$176.2M | −$31.4M | −$40.6M | −$25.0M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$616.3M ▲ 87.3% in FY2025$447.2M ▲ 1812.4% in FY2025−$25.0M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 9, 2026Quarterly results 8-K item 2.02
-
10-QNov 9, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
TG Therapeutics, Inc., New York, NY · from the 10-K filed Feb 27, 2026
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S.
- Headquarters
- New York, NY
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 9, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.